TABLE 2

Markers of oxidative stress

	Control		CPAP withdrawal		Treatment effect^#	p-value
	Baseline	2 weeks	Baseline	2 weeks	Treatment effect^#	p-value
Subjects	30		29
Overnight ODI at 2 weeks ≥4% dips·h⁻¹		3.01±3.10		45.7±18.3	+42.8 (+36.0 to +49.5)	<0.0001
Plasma MDA µmol·L⁻¹	1.43±0.34	1.39±0.31	1.36±0.44	1.38±0.47	−0.02 (−0.23 to +0.19)	0.86⁺
Plasma oxLDL mU·L⁻¹	11.1±3.72	11.6±4.85	13.0±4.20	13.2±5.02	−0.21 (−2.06 to +1.64)	0.82⁺
Plasma TAC nmol·μL⁻¹	37.7±1.71	38.0±2.31	37.5±2.37	37.1±2.14	−0.77 (−1.96 to +0.43)	0.20⁺
Urine F2-ISO ng·mL⁻¹	0.77±0.30	0.88±0.42	0.81±0.33	0.63±0.26	−0.26 (−0.42 to −0.10)	0.002
PBMC superoxide generation RLU·s⁻¹·cell⁻¹^¶	0.084±0.044	0.089±0.034	0.085±0.037	0.082±0.021	+0.02 (−0.06 to +0.09)	0.64⁺

Data are presented as n, mean±sd or mean (95% CI), unless otherwise stated. CPAP: continuous positive airway pressure; ODI: oxygen desaturation index; MDA: malondialdehyde; oxLDL: oxidised low-density lipoprotein; TAC: total antioxidant capacity; F2-ISO: F2-isoprostanes; PBMC: peripheral blood mononuclear cells; RLU: relative light units. ^#: treatment effect was controlled for the baseline value of the relevant dependent variable, age, body mass index, statins, antihypertensives and smoking status; ^¶: 13 subjects were included in this analysis (control subjects n=7, CPAP-withdrawal subjects n=6); ⁺: nonsignificant.